Article | Published:

Proteomic signature of circulating extracellular vesicles in dilated cardiomyopathy


Dilated cardiomyopathy (DCM) remains a major cause of heart failure and carries a poor prognosis despite important advances in recent years. Better disease characterization using novel molecular techniques is needed to refine its progression. This study explored the proteomic signature of plasma-derived extracellular vesicles (EVs) obtained from DCM patients and healthy controls using size-exclusion chromatography (SEC). EV-enriched fractions were analyzed by liquid chromatography-mass spectrometry (LC-MS/MS). Raw data obtained from LC-MS/MS were analyzed against the Uniprot human database using MaxQuant software. Additional analyses using Perseus software were based on the Intensity-Based Absolute Quantification (iBAQ) values from MaxQuant analyses. A total of 90.07 ± 21 proteins (227 different proteins) in the DCM group and 96.52 ± 17.91 proteins (183 different proteins) in the control group were identified. A total of 176 proteins (74.6%) were shared by controls and DCM patients, whereas 51 proteins were exclusive for the DCM group and 7 proteins were exclusive for the control group. Fibrinogen (α, β and γ chain), serotransferrin, α-1-antitrypsin, and a variety of apolipoprotein family members (C-I, C-III, D, H or β-2-glycoprotein, and J or clusterin) were clustered in SEC-EVs derived from DCM patients relative to controls (p < 0.05). Regarding Gene Ontology analysis, response to stress and protein activation-related proteins were enriched in DCM-EVs compared with controls. Thus, the present study reports the distinct proteomic signature of circulating DCM-EVs compared with control-EVs. Furthermore, we confirm that SEC obtains highly purified EV fractions from peripheral blood samples for subsequent use in determining disease-specific proteomic signatures.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Towbin JA, Bowles NE. The failing heart. Nature. 2002;415:227–33.

  2. 2.

    Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet. 2010;375:752–62.

  3. 3.

    Towbin JA, Lorts A. Arrhythmias and dilated cardiomyopathy common pathogenetic pathways? J Am Coll Cardiol. 2011;57:2169–71.

  4. 4.

    Roura S, Planas F, Prat-Vidal C, et al. Idiopathic dilated cardiomyopathy exhibits defective vascularization and vessel formation. Eur J Heart Fail. 2007;9:995–1002.

  5. 5.

    Roura S, Bayes-Genis A. Vascular dysfunction in idiopathic dilated cardiomyopathy. Nat Rev Cardiol. 2009;6:590–8.

  6. 6.

    Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.

  7. 7.

    Roura S, Gálvez-Montón C, Fernández MA, et al. Circulating endothelial progenitor cells: potential biomarkers for idiopathic dilated cardiomyopathy. J Cardiovasc Transl Res. 2016;9:80–84.

  8. 8.

    Januzzi JL Jr.. Natriuretic peptides as biomarkers in heart failure. J Investig Med. 2013;61:950–5.

  9. 9.

    Gopal DM, Sam F. New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy. J Cardiovasc Transl Res. 2013;6:516–27.

  10. 10.

    Yáñez-Mó M, Siljander PR-M, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell vesicles [Internet]. 2015;4:27066.

  11. 11.

    Lawson C, Vicencio JM, Yellon DM, et al. Microvesicles and exosomes: new players in metabolic and cardiovascular disease. J Endocrinol. 2016;228:R57–71.

  12. 12.

    Roura S, Gálvez-Montón C, de Gonzalo-Calvo D, et al. Extracellular vesicles do not contribute to higher circulating levels of soluble LRP1 in idiopathic dilated cardiomyopathy. J Cell Mol Med. 2017;21:3000–9.

  13. 13.

    Lynöe N, Sandlund M, Dahlqvist G, et al. Informed consent: study of quality of information given to participants in a clinical trial. BMJ. 1991;303:610–3.

  14. 14.

    Dagur PK, McCoy JP Jr. Collection, storage, and preparation of human blood cells. Curr Protoc Cytom. 2015;73:1–16.

  15. 15.

    Boing AN, Van Der Pol E, Grootemaat AE, et al. Single-step isolation of extracellular vesicles by size-exclusion chromatography. J Extracell Vesicles. 2014;3:23430.

  16. 16.

    Thery C, Amigorena S, Raposo G, et al. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;3:22.

  17. 17.

    Suárez H, Gámez-Valero A, Reyes R, et al. A bead-assisted flow cytometry method for the semi-quantitative analysis of extracellular vesicles. Sci Rep. 2017;7:11271.

  18. 18.

    Tyanova S, Temu T, Sinitcyn P, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016;13:731–40.

  19. 19.

    EV-TRACK Consortium, Van Deun J, Mestdagh P, et al. EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. Nat Methods. 2017;14:228–32.

  20. 20.

    Bayes-Genis A, Núñez J, Núñez E, et al. Multi-biomarker profiling and recurrent hospitalizations in heart failure. Front Cardiovasc Med. 2016;3:37. (eCollection 2016).

  21. 21.

    Sáenz-Cuesta M, Mittelbrunn M, Otaegui D. Editorial: novel clinical applications of extracellular vesicles. Front Immunol. 2015;6:381.

  22. 22.

    Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles. 2015;4:30087.

  23. 23.

    Gámez-Valero A, Monguió-Tortajada M, Carreras-Planella L, et al. Size-exclusion chromatography-based isolation minimally alters extracellular vesicles’ characteristics compared to precipitating agents. Sci Rep. 2016;6:33641.

  24. 24.

    Lowe GD. Fibrinogen assays for cardiovascular risk assessment. Clin Chem. 2010;56:693–5.

  25. 25.

    Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant metaanalysis. JAMA. 2005;294:1799–809.

  26. 26.

    Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310–20.

  27. 27.

    Appiah D, Schreiner PJ, MacLehose RF, et al. Association of plasma gamma’ fibrinogen with incident cardiovascular disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2015;35:2700–6.

  28. 28.

    Becatti M, Marcucci R, Bruschi G, et al. Oxidative modification of fibrinogen is associated with altered function and structure in the subacute phase of myocardial infarction. Arterioscler Thromb Vasc Biol. 2014;34:1355–61.

  29. 29.

    Abdo AS, Kemp R, Barham J, et al. Dilated cardiomyopathy and role of antithrombotic therapy. Am J Med Sci. 2010;339:557–60.

  30. 30.

    Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165:575–82.

  31. 31.

    Comin-Colet J, Ruiz S, Cladellas M, et al. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. J Card Fail. 2009;15:727–35.

  32. 32.

    Jankowska EA, Rozentryt P, Witkowska P, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail. 2011;17:899–906.

  33. 33.

    Enjuanes C, Klip IT, Bruguera J, et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol. 2014;174:268–75.

  34. 34.

    Van Veldhuisen DJ, Anker SD, Ponikowski P, et al. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol. 2011;8:485–93.

  35. 35.

    Gettins PG. Serpin structure, mechanism, and function. Chem Rev. 2002;102:4751–804.

  36. 36.

    Izquierdo I, Rosa I, Bravo SB, et al. Proteomic identification of putative biomarkers for early detection of sudden cardiac death in a family with a LMNA gene mutation causing dilated cardiomyopathy. J Proteom. 2016;148:75–84.

  37. 37.

    Jones SE, Jomary C. Clusterin. Int J Biochem Cell Biol. 2002;34:427–31.

  38. 38.

    Wyatt A, Yerbury J, Poon S, et al. Chapter 6: the chaperone action of clusterin and its putative role in quality control of extracellular protein folding. Adv Cancer Res. 2009;104:89–114.

  39. 39.

    Park S, Mathis KW, Lee IK. The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. Rev Endocr Metab Disord. 2014;15:45–53.

  40. 40.

    Trougakos IP, Poulakou M, Stathatos M, et al. Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol. 2002;37:1175–87.

  41. 41.

    Koller L, Richter B, Winter MP, et al. Clusterin/apolipoprotein J is independently associated with survival in patients with chronic heart failure. J Clin Lipidol. 2017;11:178–84.

Download references


We specifically acknowledge Dr. Francisco Sánchez-Madrid (Servicio de Inmunología, Hospital Universitario de la Princesa, IIS-IP, UAM; Cell-Cell Communication Laboratory, CNIC) and Dr. María Yáñez-Mó (Unidad de Investigación, Hospital Sta Cristina, IIS-IP; Departamento Biología Molecular/CBM-SO, UAM) for kindly gifting antibodies against CD9, CD63 and CD81. We also thank Beatriz González, Roser Cabanes, Margarita Rodríguez, Carmen Rivas, Nuria Benito and Alba Ros for invaluable work in the Heart Failure Clinic; Eduard Sabido and Eva Borràs from the UPF/CRG Proteomics Unit for proteomic data processing and analysis; and Hernando del Portillo (ICREA Research Professor at ISGLOBAL-IGTP) for access to the NTA instrument.


This work was supported by grants from the Ministerio de Economía, Industria y Competitividad (SAF2014-59892-R), Fundació La MARATÓ de TV3 (201405/10, 201502, 201516), Societat Catalana de Cardiologia, Generalitat de Catalunya (SGR 2014, CERCA Programme) and the Fundació Bancària La Caixa. This work was also funded by the Red de Terapia Celular—TerCel (RD16/0011/0006), CIBER Cardiovascular—(CB16/11/00403), and Fondo de Investigación Sanitaria, Instituto de Salud Carlos III (FIS PI14/01682) as part of the Plan Nacional de I+D+I cofounded by ISCIII-Sudirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER).

Author information

Conflict of interest

The authors declare that they have no conflict of interest.

Correspondence to Francesc E. Borràs or Antoni Bayes-Genis.

Electronic supplementary material

  1. Supplemental Table 1

  2. Supplementary Figure 1

  3. Supplementary Figure 1 legend

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5